Pharmaceuticals Company Announces Advancement In Pharmacokinetics Study

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, has announced that it is advancing to the second cohort in its pharmacokinetics study of AD04. This progression follows the successful completion of the first cohort, marking a massive milestone for the company's lead investigational drug aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients. $Adial Pharmaceuticals (ADIL.US)$